Enzolytics, Inc. is a biotechnology company, which engages in the development and commercialization of drugs for infectious disease treatments. The company is headquartered in Plano, Texas. The company went IPO on 2008-12-29. The firm is focused on commercializing its licensed proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases to include the additional contracted areas of sales, marketing and distribution of medical devices, medical testing and nutraceutical products. Its subsidiaries include BioClonetics lmmunotherapy, Inc. and Biogenysis, Inc.
ENZC stock price ended at $0 on 水曜日, after rising NaN%
On the latest trading day May 06, 2026, the stock price of ENZC rose by NaN%, climbing from $0.00 to $0.00. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $0.00 and a high of $0.00. Notably, trading volume dropped by 1.5M shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 2.7M shares were traded, equating to a market value of approximately --.